Detection of residual neuroblastoma cells in bone marrow: Comparison of flow cytometry with immunocytochemistry

Cytometry Part B - Clinical Cytometry

Volumn 61, Issue 1, 2004, Pages 9-19

  Swerts, Katrien ^a   De Moerloose, Barbara ^a   Dhooge, Catharina ^a   Brichard, Bénédicte ^b   Benoit, Yves ^a   Laureys, Geneviève ^a   Philippé, Jan ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Flow cytometry; Immunocytochemistry; Minimal residual disease; Neuroblastoma

Indexed keywords

CD45 ANTIGEN; CD56 ANTIGEN; CD81 ANTIGEN; CD9 ANTIGEN; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD2; GANGLIOSIDE GD2 ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER DIAGNOSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FLOW CYTOMETRY; FOUR COLOR FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; INTERMETHOD COMPARISON; MALE; MINIMAL RESIDUAL DISEASE; MONONUCLEAR CELL; NEUROBLASTOMA CELL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SCREENING;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD45; ANTIGENS, CD56; BIOPSY; BONE MARROW CELLS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CYTOPLASM; FEMALE; FLOW CYTOMETRY; GANGLIOSIDES; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; MEMBRANE GLYCOPROTEINS; NEOPLASM CIRCULATING CELLS; NEUROBLASTOMA; PHENOTYPE; SENSITIVITY AND SPECIFICITY; STEM CELLS;

EID: 4544272181     PISSN: 15524949     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.b.20019     Document Type: Article

References (37)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In: Pizzo PA, Poplack DG, editors. Principles and practice of pediatric oncology. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1997. p 761-797.
2. Philip T, Ladenstein R, Lasset C, Hartmann O, Zucker JM, Pinkerton R, Pearson ADJ, Klingebiel T, Garaventa A, Kremens B, Bernard JL, Rosti G, Chauvin F. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 14 years of European experience and conclusions. Eur J Cancer 1997;33:2130-2135.
3. Cheung IY, Chi SN, Cheung NKV. Prognostic significance of GAGE detection in bone marrows on survival of patients with metastatic neuroblastoma. Med Pediatr Oncol 2000;35:659-602.
4. Seeger RC, Reynolds CP, Gallego R, Stram DO, Gerbing R, Matthay KK. Quantitative tumor cell content of bone marrow and blood as predicitor of outcome in stage IV neuroblastoma: a children's cancer group study. J Clin Oncol 2000;18:4007-4076.
5. Fukuda M, Miyajima Y, Miyashita Y, Horibe K. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study. J Pediatr Hematol Oncol 2001;23:10-13.
6. Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba H, Miyashita Y. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 2001;36:203-204.
7. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Swift P, Shimada H, Black CT, Brodeur GM, Gerbing R, Reynolds CP. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 1999;341:1165-1173.
8. Moss TJ, Sanders DG, Lasky LG, Bostrom B. Contamination of peripheral-blood stem-cell harvests by circulating neuroblastoma-cells. Blood 1990;76:1879-1883.
9. Rill DR, Santana VM, Roberts WM, Nilson T, Bowman LC, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone-marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994;84:380-383.
10. Tsang KS, Li CK, Tsoi WC, Leung Y, Shing MMK, Chik KW, Lee V, Ng MHL, Yuen PMP. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction. Cancer 2003;97:2887-2897.
11. Cheung NKV, Heller G, Kushner BH, Liu CY, Cheung IY. Detection of metastatic neuroblastoma in bone marrow: when is routine marrow histology insensitive? J Clin Oncol 1997;15:2807-2817.
12. Komada Y, Zhang XL, Zhou YW, Inaba H, Deguchi T, Azuma E, Sakurai M. Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer 1998; 82:591-599.
13. Ambros PF, Mehes G, Hattinger C, Ambros IM, Leugmayr A, Ladenstein R, Gadner H. Unequivocal identification of disseminated tumor cells in the bone marrow by combining immunological and genetic approaches-functional and prognostic information. Leukemia 2001; 15:275-277.
14. Nagai J, Ishida Y, Koga N, Tanaka Y, Ohnuma K, Toyoda Y, Katoh A, Hayabuchi Y, Kigasawa H. A new sensitive and specific combination of CD81/CD56/CD45 monoclonal antibodies for detecting circulating neuroblastoma cells in peripheral blood using flow cytometry. J Pediatr Hematol Oncol 2000;22:20-26.
15. Burchill SA, Lewis I, Abrams KR, Riley R, Imeson J, Pearson A, Pinkerton CR, Selby P. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 2001;19:1795-1801.
16. Cheung IY, Cheung NKV. Quantitation of marrow disease in neuroblastoma by real-time reverse transcription-PCR. Clin Cancer Res 2001;7:1698-1705.
17. Mehes G, Ambros PF, Gadner H. Detecting disseminated solid tumor cells in hematopoietic samples: methodological aspects. Haematologia 2001;31:97-109.
18. Warzynski MJ, Graham DM, Axtell RA, Higgins JV, Hammers YA. Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients. Cytometry 2002;50B:298-304.
19. Träger C, Kogner P, Lindskog M, Ponthan F, Kullman A, Kagedal B. Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem 2003;49:104-112.
20. Wu Z, Schwartz E, Seeger RC, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res 1986: 46:440-443.
21. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1987;47:1098-1104.
22. Ruan S, Lloyd KO. Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns. Cancer Res 1992; 52:5725-5731.
23. Lammie GA, Cheung NKV, Gerald W, Rosenblum M. Ganglioside GD2 expression in the human nervous system and in neuroblastomas: an immunohistochemical study. Int J Oncol 1993;3:909-915.
24. Komada Y, Azuma E, Kamiya H, Sakurai M. Phenotypic profile of human neuroblastoma cell lines: association with morphological characteristics. Br J Haematol 1986;54:711-715.
25. Mechterheimer G, Barth T, Ludwig R, Staudter M, Med C, Moller P. Differential expression of leukocyte differential antigens in small round blue cell sarcomas. Cancer 1993;71:237-248.
26. Oren R, Takahashi S, Doss C, Levy R, Levy S. TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol 1990;10:4007-4015.
27. Lipinski M, Hirsch MR, Deagostini-Bazin H, Yamada O, Tursz T, Goridis C. Characterization of neural cell adhesion molecules (NCAM) expressed by Ewing and neuroblastoma cell lines. Int J Cancer 1987;40:81-86.
28. Cheung NKV, Van Hoff DD, Strandjord SE, Coccia PF. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986;4:363-369.
29. Chang TK, Li CY, Smithson WA. Immunocytochemical study of small round cell tumors in routinely processed specimens. Arch Pathol Lab Med 1989;13:1343-1348.
30. Campana D, Coustan-Smith E. Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia. Best Pract Res Clin Haematol 2002;15:1-19.
31. Beiske K, Myklebust AT, Aamdal S, Langholm R, Jakobsen E, Fodstad Ø. Detection of bone marrow metastases in small cell lung cancer patients. Am J Pathol 1992;141:531-538.
32. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, Macdonald S, Pulford KAF, Stein H, Mason DY. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-229.
33. Faulkner LB, Garaventa A, Paoli A, Tintori V, Tamburini A, Lacitignola L, Veltroni M, Lo Piccolo MS, Viscardi E, Milanaccio C, Tondo A, Spinelli S, Bernini G, De Bernardi B. In vitro cytoreduction studies and cell sorting-enhanced tumor-cell detection in high-risk neuroblastoma patients: implications for leukapheresis strategies. J Clin Oncol 2000; 18:3829-3836.
34. Mehes G, Luegmayr A, Ambros IM, Ladenstein R, Ambros PF. Combined automatic immunological and molecular cytogenetic analysis allows exact identification and quantification of tumor cells in the bone marrow. Clin Cancer Res 2001;7:1969-1975.
35. Cheung NKV, Kushner BH, La Quaglia M, Kramer K, Gollamudi S, Heller G, Gerald W, Yeh S, Finn R, Larson SM, Wuest D, Byrnes M, Dantis E, Mora J, Cheung IY, Rosenfield N, Abramson S, O'Reilly RJ. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol 2001;36: 227-230.
36. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-226.
37. Rogers DW, Treleaven JG, Kemshead J, Pritchard J. Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma. J Clin Pathol 1989;42:442-426.